DAX20.642 -5,0%ESt504.878 -4,6%Top 10 Crypto11,92 +8,5%Dow38.740 -4,5%Nas15.797 -4,6%Bitcoin76.927 +2,2%Euro1,0950 -0,9%Öl66,33 -5,0%Gold3.031 -2,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Tesla A1CX3T Rheinmetall 703000 Apple 865985 Amazon 906866 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Bank 514000 Lufthansa 823212 Volkswagen (VW) vz. 766403 BASF BASF11 Infineon 623100 Microsoft 870747 Allianz 840400 Nike 866993
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen auf rasanter Talfahrt -- DAX geht massiv tiefer ins Wochenende -- US-Zölle: China schlägt zurück -- Aktien von Rheinmetall, RENK & HENSOLDT im Minus -- Novo Nordisk, Apple im Fokus
Top News
US-Glyphosat-Streit: Bayer wendet sich an höchstes US-Gericht US-Glyphosat-Streit: Bayer wendet sich an höchstes US-Gericht
So entwickeln sich Goldpreis & Co. am Freitagabend So entwickeln sich Goldpreis & Co. am Freitagabend
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

PTC Therapeutics Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
39,00 EUR -2,80 EUR -6,70 %
STU
43,47 USD -3,28 USD -7,02 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.3,33 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W0MW

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS69366J2006

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPTCT

PTC Therapeutics Aktien News

DatumMeistgelesen
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
PR NewswirePTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results 
PR NewswirePTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswireCHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
PR NewswirePTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
PR NewswireAustralian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
PR NewswirePTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
PR NewswireCHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
PR NewswirePTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
PR NewswirePTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
PR NewswirePTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
PR NewswirePTC Therapeutics Announces Strategic Pipeline Prioritization
PR NewswirePTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
PR NewswirePTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
PR NewswirePTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswirePTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
PR NewswirePTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results
PR NewswireStuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics
PR NewswirePTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PR NewswirePTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
PR NewswirePTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conference
PR NewswireNICE Recommends Reimbursement for Translarna™
PR NewswireNICE Recommends Reimbursement for Translarna™
Wer­bung

PTC Therapeutics News

PTC Therapeutics News: auf dieser Seite finden Sie alle PTC Therapeutics News und Nachrichten zur PTC Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch PTC Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um PTC Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.